These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 24449211

  • 21. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM.
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
    Kloos R, van der Sluis IM, Mastrobattista E, Hennink W, Pieters R, Verhoef JJ.
    Br J Haematol; 2020 May; 189(3):442-451. PubMed ID: 31883112
    [Abstract] [Full Text] [Related]

  • 26. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT.
    Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
    [Abstract] [Full Text] [Related]

  • 27. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
    Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH.
    Cancer; 2011 Jan 15; 117(2):238-49. PubMed ID: 20824725
    [Abstract] [Full Text] [Related]

  • 28. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.
    Verma A, Chen K, Bender C, Gorney N, Leonard W, Barnette P.
    Pediatr Hematol Oncol; 2019 Aug 15; 36(5):277-286. PubMed ID: 31296092
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
    Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui CH, Relling MV.
    J Clin Oncol; 2000 Apr 15; 18(7):1525-32. PubMed ID: 10735901
    [Abstract] [Full Text] [Related]

  • 33. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, Benoit Y, Robert A, Manel AM, Vilmer E, Otten J, Philippe N.
    Blood; 2002 Apr 15; 99(8):2734-9. PubMed ID: 11929760
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C, Taguchi F, Goto H, Koh K, Tomizawa D, Ohara A, Manabe A.
    Pediatr Blood Cancer; 2017 Sep 15; 64(9):. PubMed ID: 28244643
    [Abstract] [Full Text] [Related]

  • 36. Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poirée M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cavé H, Rohrlich P, Bertrand Y, Benoit Y, Children–s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC).
    Haematologica; 2017 Oct 15; 102(10):1727-1738. PubMed ID: 28751566
    [No Abstract] [Full Text] [Related]

  • 37. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 15; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
    Kloos RQ, Pieters R, Escherich G, van der Sluis IM.
    Pediatr Blood Cancer; 2016 Nov 15; 63(11):1928-34. PubMed ID: 27376478
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.